Group B Streptococcal polysaccharide toxin (GBS Toxin, CM101) causes "Early Onset Disease" in neonates by binding to a pathoangiogenesis capillary endothelium receptor lectin HP59 (1,2).The CM101/HP59 complex activates complement and causes an inflammatory cytokine cascade which targets CD69 pos. activated granulocytes to destroy the neonate lung neovasculature and surrounding tissue.HP59 pos. capillaries are only found in humans older than 10 days post-partum in tumor neovasculature and wound healing.Therefore CM101 has been tested as a solid tumor therapeutic in animal studies and in a Phase I, IND-based, refractory patient clin. trial performed at Vanderbilt University Cancer Center (3).The results showed an unusually high 33% effectivity with refractory, stage 4 patients with an estimated 4-5 mo life expectancy, extending the lives of 3 patients 18 mo, 4 years and 10 years.Due to a business failure, CM101 was not taken through Phase II trials.TumorEnd, LLC has licensed patents to this technol. from Vanderbilt University, and is working toward advancing clin. trials in canines and humans, in a less than optimum financing climate.Details of the technol. and business efforts will be presented.(1).See Wikipedia under "HP59" (2).Fu, C.,Bardhan,S, Cetateanu, N.D., Wamil, B.D., Wang, Y., Yan, H-P., Carter, C.E., Shi, E., Venkov.V.Yakes, F.M., Page, D.L., Lloyd, R.S., Hellerqvist, C.G..Identification of a Novel Membrane Protein HP59 with Therapeutic Potential as a Target of Tumor Angiogenesis.Clin. Cancer Research, 7: 4182-4194, 2001 (3)DeVore, R.F., Hellerqvist, C.G., Wakefield, G.B., Wamil, B.D., Thurman, G.B., Minton, P.A., Sundell, H.W., Yan, H.-P., Carter, C.E., Wang, Y.-F., York, G.E., Zhang, M.-H., Johnson, D.H.A phase I study of the antineovascularization drug CM101.J.Clin.Can.Res.3: 365-372, 1997.